IN8bio (NASDAQ:INAB) Releases Earnings Results, Beats Expectations By $0.10 EPS

IN8bio (NASDAQ:INAB) released its quarterly earnings data on Thursday. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10, FiscalAI reports.

IN8bio Price Performance

NASDAQ:INAB traded up $0.10 during trading hours on Friday, hitting $0.93. 33,376 shares of the company’s stock traded hands, compared to its average volume of 39,109. IN8bio has a 52 week low of $0.80 and a 52 week high of $2.73. The business’s fifty day simple moving average is $1.13 and its two-hundred day simple moving average is $1.42.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell therapeutic and ?? T cell engager (TCE) product candidates to address unmet medical needs. ?? T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic ?? T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.